Rapidly Growing Pipelines of Transformative Medicines

For most Alzheimer’s patients, there is no clear trajectory of disease progression or worsening symptoms. In fact, even clinical presentation can be widely different from individual to individual, suggesting that Alzheimer’s is less of a disease and more of a syndrome. Integrating brain gene expression and AD marker data offers the potential to stratify patients into subgroups with unique biology and identify targets specific to these subgroups.